ASCO GI: Biologic Helps in Esophageal Cancer (CME/CE)
SAN FRANCISCO (MedPage Today) — Three-fourths of patients with advanced esophageal cancer had major responses when cetuximab (Erbitux) was added to chemoradiation, investigators reported here.
SAN FRANCISCO (MedPage Today) — Three-fourths of patients with advanced esophageal cancer had major responses when cetuximab (Erbitux) was added to chemoradiation, investigators reported here.
Comments are closed.
All rights reserved. © UK. Site Map | Contact us | About us | Contributors | Supporters | Terms & Conditions
This site complies with the HONcode standard for trustworthy health information: verify here.